Quantcast
  

Friday, April 18, 2014         

 Print   Email   Comment | View 1 Comments   Most Popular   Save   Post   Retweet

UH discovery may help identify people with higher cancer risk

By Star-Advertiser staff

POSTED:
LAST UPDATED: 05:12 p.m. HST, Sep 07, 2012


University of Hawaii cancer researchers say a new discovery allows physicians to visually identify individuals who may carry a gene mutation present in persons with a higher risk of skin cancer.

The visual marker also applies to those who are at higher risk of mesothelioma, a cancer associated with asbestos exposure affecting the membrane lining of the lungs and abdomen.

The findings were published in the Aug. 30 issue of the Journal of Translational Medicine.

University researchers said persons are at higher risk of contracting the two cancers and can be identified by testing for the presence of certain mole-like tumors that are noncancerous, flat or slightly elevated, and pigmented skin lesions that have the BAP1 gene defect.

Researchers warned that people with the BAP1 gene defect should reduce their exposure to environmental risks factors, such as ultraviolet radiation for melanoma and avoid the fibrous mineral “erionite” and asbestos exposure for mesothelioma.

“Identifying this gene as a cause of several cancers can tell us who is at risk in a family before the cancer develops,” said Dr. Michele Carbone, director of the University’s Cancer Center and professor of pathology at John A. Burns School of Medicine, in a release Wednesday. “We can advise patients to undergo routine exams and genetic testing for early diagnoses and treatment."

Carbone and colleagues have already patented the gene-testing, a process performed exclusively at the Queen’s Medical Center.

The latest discovery builds on Carbone’s previous discovery that individuals who carry BAP1 mutations are susceptible to developing mesothelioma and melanoma of the eye, according to the University of Hawaii Cancer Center.







 Print   Email   Comment | View 1 Comments   Most Popular   Save   Post   Retweet

COMMENTS
(1)
You must be subscribed to participate in discussions
By participating in online discussions you acknowledge that you have agreed to the TERMS OF SERVICE. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. Because only subscribers are allowed to comment, we have your personal information and are able to contact you. If your comments are inappropriate, you may receive a warning, and if you persist with such comments you may be banned from posting. To report comments that you believe do not follow our guidelines, email commentfeedback@staradvertiser.com.
Leave a comment

Please login to leave a comment.
hotterotter wrote:
The linked article below indicates that MC (Michele Carbone, MD) Director of the UH Cancer Center has a patent pending on the BAP1 gene test. Does he gain financially from this patent or would the University of Hawaii Cancer Center? Remember what he says, you can't have two jobs at the same time... Competing interests MC has a patent pending on BAP1. MC has also received compensation for pathological diagnoses and honoraria for speaking engagements on the topics of genetics and mesothelioma. No other disclosures were reported. All authors read and approved the final manuscript. http://www.translational-medicine.com/content/10/1/179 BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs Michele Carbone12*, Laura Korb Ferris6, Francine Baumann1, Andrea Napolitano13, Christopher A Lum14, Erin G Flores1, Giovanni Gaudino1, Amy Powers125, Peter Bryant-Greenwood125, Thomas Krausz7, Elizabeth Hyjek8, Rachael Tate9, Joseph Friedberg10, Tracey Weigel11, Harvey I Pass12 and Haining Yang12
on September 17,2013 | 06:16PM
IN OTHER NEWS
Breaking News